Global Paediatric Interventional Cardiology Market Analysis to 2029

Featuring Medtronic, NeMED, GE Healthcare and Boston Scientific Among Others

The “Paediatric Interventional Cardiology Market Analysis by Device Type and by Region – Global Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.

The paediatric interventional cardiology market size is estimated to be USD 1,581.3 million in 2021 and is expected to witness a CAGR of 11.18% during the forecast period 2022-2029.

Companies Mentioned:

  • St. Jude Medical Inc. (U.S.)
  • Medtronic Inc. (U.S.)
  • W.L. Gore & Associates Inc. (U.S.)
  • Edwards Lifesciences Corp (U.S.)
  • NuMED Inc. (U.S.)
  • Cordis Corporation (U.S.)
  • GE Healthcare (U.K.)
  • Siemens Healthcare (Germany)
  • Boston Scientific (U.S.)
  • Abbott Vascular (U.S.)

The increased rates of congenital heart disease and FDA initiatives to streamline the regulatory process, technical advances, which have resulted in the introduction of new and improved products is expected to drive the market.

However, changing stringency of regulatory procedures and presence of complex regulatory procedures is expected to restrain the market growth.

By Device Type

Based on device type, the market is segregated into transcatheter heart valves and congenital heart defect closure devices. In 2021, the congenital heart defect closure devices segment accounted for the highest revenue share due to a rising understanding of the importance of paediatric interventional cardiology devices and rising instances of congenital impairments.

Regional Markets

In 2021, Asia Pacific region accounted for the highest revenue in the paediatric interventional cardiology market and is expected to maintain its dominance during the forecast period. The increase in government funding for developing paediatric care facilities, and investments by prominent players in the APAC region. are all contributing to the market expansion.

Segmentation: Paediatric Interventional Cardiology Market Report 2021-2029

By Device Type (Revenue, USD Million)

  • Transcatheter Heart Valves
  • Congenital Heart Defect Closure Devices

By Region (Revenue, USD Million)

North America

  • U.S
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

For more information about this report visit https://www.researchandmarkets.com/r/an873x

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”